Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 09/30 05:35:16 pm
67.64 EUR   -0.57%
09:59a SANOFI : and Regeneron Announce Positive Dupixent® (dupilumab) Phase..
09:52a SANOFI : and Regeneron Announce Positive Dupixent® (dupilumab) Phase..
08:01a SANOFI : Regeneron and Sanofi Announce Positive Dupixent® (dupilumab..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SANOFI : PRESS RELEASE : Former Research Chemist At Global Pharmaceutical Company Sentenced To 18 Months In Prison For Theft Of Trade Secrets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 07:17pm CEST

United States Attorney

District of New Jersey

FOR IMMEDIATE RELEASE CONTACT: Rebekah Carmichael

May 7, 2012 Office of Public Affairs

www.justice.gov/usao/nj (973) 645-2888

FORMER RESEARCH CHEMIST AT GLOBAL PHARMACEUTICAL COMPANY

SENTENCED TO 18 MONTHS IN PRISON FOR THEFT OF TRADE SECRETS

TRENTON, N.J. - A former research chemist with global pharmaceutical company

sanofi-aventis ("sanofi") was sentenced today to 18 months in prison for stealing sanofi's trade

secrets and making them available for sale through Abby Pharmatech, Inc. ("Abby"), the U.S.

subsidiary of a Chinese chemicals company, U.S. Attorney Paul J. Fishman announced.

Yuan Li, 30, of Somerset, N.J., a Chinese national, previously pleaded guilty to an

Information charging her with one count of theft of trade secrets. Li entered her guilty plea

before U.S. District Judge Joel A. Pisano, who also imposed the sentence today in Trenton

federal court.

According to documents filed in this case and statements made in court:

Sanofi is a global healthcare company with U.S. headquarters in Bridgewater, N.J.

Among other things, sanofi is engaged in the development, manufacture and marketing of

healthcare products including the prescription drugs Allegra, Plavix, Copaxone and Ambien.

Li worked as a research scientist at sanofi's Bridgewater headquarters from October 2006

through June 2011, where she directly assisted in the development of a number of compounds

that sanofi viewed as potential building blocks for future drugs. These compounds were sanofi's

trade secrets and had not been disclosed outside of sanofi in any manner, including by means of a

patent application.

While employed at sanofi, Li was also a 50 percent partner in Abby, which is engaged in

the sale and distribution of pharmaceuticals.

Li admitted that between January 2010 and June 2011, she accessed an internal sanofi

database and downloaded information related to a number of sanofi compounds, including their

chemical structures, onto her sanofi-issued laptop computer. She also admitted she then

transferred the information to her personal home computer by sending it to her personal e-mail

address or via a USB thumb drive.

Li acknowledged that she made the stolen compounds available for sale on Abby's

website.

In addition to the prison term, Judge Pisano sentenced Li to serve two years of supervised

release and ordered her to pay $131,000 in restitution.

U.S. Attorney Fishman credited special agents of the FBI, under the direction of Special

Agent in Charge Michael B. Ward, with the investigation.

The government is represented by Assistant U.S. Attorney Gurbir S. Grewal of the

Computer Hacking and Intellectual Property Section of the U.S. Attorney's Office Economic

Crimes Unit in Newark.

12-159 ###

Defense counsel: Paul Brickfield Esq., River Edge, N.J.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:42p SANOFI : $37.62 Million Federal Contract Awarded to Sanofi-Aventis U.S.
09:59a SANOFI : and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic De..
09:52a SANOFI : and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic De..
08:01a SANOFI : Regeneron and Sanofi Announce Positive Dupixent® (dupilumab) Phase 3 At..
09/30 SANOFI : - Fighting cardiovascular diseases this World Heart Day
09/30 SANOFI : Appoints Alan Main to Executive Committee and Executive Vice President,..
09/30 ZEALAND PHARMA AKTIESELSKABET : upsizes its private placement of new shares and ..
09/30 ZEALAND PHARMA AKTIESELSKABET : launches private placement of a limited number o..
09/30DJNovo Nordisk Announces Job Cuts
09/30 SANOFI : deal raises concerns about Boehringer
More news
Sector news : Pharmaceuticals - NEC
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30 GlaxoSmithKline to pay $20 million to settle U.S. foreign bribery case
09/30DJGLAXOSMITHKLINE : to Pay $20 Million to Settle SEC Bribery Probe
09/30DJSHIRE : Files 8K - Other Events
09/30DJNovo Nordisk Announces Job Cuts
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/30 MannKind-Afrezza Scripts Slide - What Investors Need To Think About Sooner Ra..
09/30 AMGEN GETS BUSY; MANY NEWS ITEMS : Anything Good Yet?
09/30 Sanofi announces thematic call on Dupilumab
09/30 Healthcare ratings roundup - new coverage
09/29 Yellen And Clinton Combo To Take Market Higher
Advertisement
Financials (€)
Sales 2016 36 859 M
EBIT 2016 9 283 M
Net income 2016 5 275 M
Debt 2016 5 441 M
Yield 2016 4,34%
P/E ratio 2016 15,51
P/E ratio 2017 14,22
EV / Sales 2016 2,51x
EV / Sales 2017 2,52x
Capitalization 87 191 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Average target price 82,5 €
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-13.94%98 005
JOHNSON & JOHNSON15.00%323 189
ROCHE HOLDING LTD.-12.52%214 851
NOVARTIS AG-11.00%207 776
PFIZER INC.4.93%205 444
MERCK & CO., INC.18.16%172 577
More Results